Ishita Drugs and Industries Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Jagdishprasad Agrawal

Algemeen directeur

₹5.1m

Totale compensatie

Percentage CEO-salaris	100.0%
Dienstverband CEO	no data
Eigendom CEO	8.7%
Management gemiddelde ambtstermijn	geen gegevens
Gemiddelde ambtstermijn bestuur	5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Jagdishprasad Agrawal's beloning veranderd ten opzichte van Ishita Drugs and Industries's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	₹7m
Jun 30 2024	n/a	n/a	₹8m
Mar 31 2024	₹5m	₹5m	₹7m
Dec 31 2023	n/a	n/a	₹6m
Sep 30 2023	n/a	n/a	₹6m
Jun 30 2023	n/a	n/a	₹5m
Mar 31 2023	₹5m	₹5m	₹6m
Dec 31 2022	n/a	n/a	₹8m
Sep 30 2022	n/a	n/a	₹8m
Jun 30 2022	n/a	n/a	₹8m
Mar 31 2022	₹4m	₹4m	₹8m
Dec 31 2021	n/a	n/a	₹9m
Sep 30 2021	n/a	n/a	₹9m
Jun 30 2021	n/a	n/a	₹9m
Mar 31 2021	₹3m	₹3m	₹8m
Dec 31 2020	n/a	n/a	₹6m
Sep 30 2020	n/a	n/a	₹5m
Jun 30 2020	n/a	n/a	₹5m
Mar 31 2020	₹3m	n/a	₹5m
Dec 31 2019	n/a	n/a	₹5m
Sep 30 2019	n/a	n/a	₹4m
Jun 30 2019	n/a	n/a	₹4m
Mar 31 2019	₹3m	₹3m	₹4m
Dec 31 2018	n/a	n/a	₹3m
Sep 30 2018	n/a	n/a	₹3m
Jun 30 2018	n/a	n/a	₹3m
Mar 31 2018	₹2m	₹2m	₹2m

Compensatie versus markt: De totale vergoeding ($USD 60.52K ) Jagdishprasad } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 42.72K ).

Compensatie versus inkomsten: De vergoeding van Jagdishprasad is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Jagdishprasad Agrawal

no data

Tenure

₹5,100,000

Compensatie

Mr. Jagdishprasad G. Agrawal serves as Chairman of the Board of Directors and Managing Director of Ishita Drugs and Industries Limited (formerly known as Ishita Drugs & Industries Limited) Mr. Agrawal has...

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jagdishprasad Agrawal	Chairman & MD	no data	₹5.10m	8.7% ₹ 22.4m
Abha Agrawal	Non-Executive Director	32.5yrs	geen gegevens	8.37% ₹ 21.5m
Arvind Sapkal	Independent Non-Executive Director	5yrs	geen gegevens	geen gegevens
Dhwani Solanki	Non Executive Independent Director	less than a year	geen gegevens	geen gegevens

5.0yrs

Gemiddelde duur

69yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 524400 wordt beschouwd als ervaren (gemiddelde ambtstermijn 5 jaar).

Ishita Drugs and Industries Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Ishita Drugs and Industries Limited Appoints Dhwani Solanki as an Independent Non-Executive Director

Ishita Drugs and Industries Limited, Annual General Meeting, Sep 30, 2024

Ishita Drugs and Industries Limited, Annual General Meeting, Sep 27, 2023

Ishita Drugs and Industries Limited, Annual General Meeting, Sep 27, 2023

Insufficient new directors

Ishita Drugs and Industries Limited, Annual General Meeting, Sep 30, 2022

Recent updates

Investor sentiment improves as stock rises 17%

Second quarter 2025 earnings released: EPS: ₹0.65 (vs ₹0.70 in 2Q 2024)

Ishita Drugs and Industries Limited to Report Q2, 2025 Results on Nov 12, 2024

Ishita Drugs and Industries Limited Appoints Dhwani Solanki as an Independent Non-Executive Director

Ishita Drugs and Industries Limited, Annual General Meeting, Sep 30, 2024

New major risk - Share price stability

First quarter 2025 earnings released: EPS: ₹0.49 (vs ₹0.46 in 1Q 2024)

Ishita Drugs and Industries Limited to Report Q1, 2025 Results on Aug 13, 2024

Investor sentiment improves as stock rises 20%

Now 22% overvalued after recent price rise

Investor sentiment improves as stock rises 21%

Full year 2024 earnings released: EPS: ₹2.50 (vs ₹1.93 in FY 2023)

Ishita Drugs and Industries Limited to Report Q4, 2024 Results on May 30, 2024

Third quarter 2024 earnings released: EPS: ₹0.40 (vs ₹0.38 in 3Q 2023)

Ishita Drugs and Industries Limited to Report Q3, 2023 Results on Feb 13, 2024

New major risk - Share price stability

Investor sentiment improves as stock rises 15%

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: ₹0.70 (vs ₹0.39 in 2Q 2023)

Investor sentiment improves as stock rises 16%

Ishita Drugs and Industries Limited, Annual General Meeting, Sep 27, 2023

Ishita Drugs and Industries Limited, Annual General Meeting, Sep 27, 2023

First quarter 2024 earnings released: EPS: ₹0.46 (vs ₹0.56 in 1Q 2023)

Ishita Drugs and Industries Limited to Report Q1, 2024 Results on Aug 12, 2023

New major risk - Share price stability

Investor sentiment improves as stock rises 20%

Full year 2023 earnings released: EPS: ₹1.93 (vs ₹2.69 in FY 2022)

Third quarter 2023 earnings released: EPS: ₹0.38 (vs ₹0.52 in 3Q 2022)

Ishita Drugs and Industries Limited to Report Q3, 2023 Results on Feb 14, 2023

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹0.39 (vs ₹0.47 in 2Q 2022)

Investor sentiment improved over the past week

Ishita Drugs and Industries Limited, Annual General Meeting, Sep 30, 2022

First quarter 2023 earnings released: EPS: ₹0.56 (vs ₹0.46 in 1Q 2022)

Ishita Drugs and Industries Limited to Report Q1, 2023 Results on Aug 13, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Ishita Drugs and Industries Limited to Report Q3, 2022 Results on Feb 14, 2022

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS ₹0.47 (vs ₹0.51 in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹2.77 (vs ₹1.83 in FY 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Company Secretary & Compliance Officer has left the company

Third quarter 2021 earnings released: EPS ₹0.46 (vs ₹0.41 in 3Q 2020)

Ishita Drugs and Industries Limited Announces Resignation of Vijay Shah from the Post of Company Secretary and Compliance Officer

Ishita Drugs and Industries Limited to Report Q3, 2021 Results on Feb 04, 2021

Investor sentiment improved over the past week

New 90-day high: ₹34.50

Investor sentiment improved over the past week

New 90-day high: ₹28.80

New 90-day high: ₹26.60

Market bids up stock over the past week

Market pulls back on stock over the past week

New 90-day high: ₹24.75

Ishita Drugs & Industries Limited to Report Q1, 2021 Results on Aug 13, 2020

New 90-day high - ₹24.15

First quarter earnings released

New 90-day high - ₹18.60

Analyse CEO-vergoeding

CEO